How gene-therapy treated mice in space may help shape the science of vision loss diseases

This week, biotech Oculogenex landed an early, but essential, endorsement from the Food and Drug Administration (FDA), the company’s CEO and founder Hema Ramkumar told Fast Company, for a therapy to treat an eye-wasting disease that’s the leading cause of irreversible vision loss in elderly Americans. The regulatory milestone isn’t an approval for the drug itself, but a significant “go-ahead” in the minutiae of how any drug is developed that stands on its own merits. It’s an endorsement of Oculogenex’s strategy for a planned mid-stage clinical trial in intermediate age-related macular degeneration (AMD).

But the boilerplate of drug approval bureaucracy isn’t the full story here. It’s just one chapter in a saga of scientific discovery that blends cutting-edge medical and rocket technologies–wherein NASA, SpaceX, Oculogenex, and a few dozen frontier-breaking space-bound mice joined forces to explore the roots of a degenerative disease that robs millions of their eyesight and independence but has few effective treatments–with a boost from the unique advantages microgravity affords researching the retina.

That story began in March, when 40 mice treated with an experimental Oculogenex gene therapy voyaged up to the International Space Station (ISS) on a SpaceX rocket. This, says Ramkumar, a physician-scientist who specializes in complex eye disorders and veteran clinical trial investigator in the space, was a first-of-its-kind mission in gene therapy drug research funded by NASA’s CASIS unit with help from MassChallenge and Boeing to advance Oculogenex’s pipeline for common-but-vexing eye diseases in serious need of exploration.

AMD is a common disease with two distinct forms–wet AMD and dry AMD–but the latter makes up for 85-90% of diagnosed cases, according to the American Macular Degeneration Foundation. Simply put, both kinds of AMD can put you at risk of blurry or impaired vision, though wet AMD is far more severe and might require treatments such as regular eye injections. At that point, abnormal blood vessels beneath the retina begin leaking blood and fluid (hence, “wet” AMD). One biological twist? Dry AMD can eventually morph into wet AMD, and there’s “no treatment for late stage dry AMD,” per the National Institutes of Health (NIH)

AMD research has a long way to go generally, says Ramkumar, especially when it comes to sussing out the exact biological foes that erode your central vision function and stop their irreversible advance. 

That research is more complicated on Earth because of how complex the disease is and how it might progress over time; age, diet, and lifestyle choices such as smoking are clear risk factors because they can cause something called “oxidative stress,” a chemical imbalance which leads to cell damage in your eyes. 

Ramkumar likens it a bit to how liver disease progresses from inflammation that might not cause any symptoms at first but could eventually lead to cell death that causes irreparable harm; figuring out how to staunch that advance could prove a boon to millions. But there aren’t a lot of ways to quickly emulate the progression of the disease on Earth.

“Usually, to get this kind of mild oxidative stressor in an animal experiment, I was getting several year old animals, aging them, feeding them,” said Ramkumar. “By the way, feeding them McDonalds is a way to get macular degeneration, a high-fat diet. And so all these things were taking way too long. And they were variable.”

But in the microgravity of space, that oxidative stress process appears to ramp up rapidly and result in the kind of retinal damage associated with intermediate dry AMD–the target patient population for Oculogenex’s experimental gene therapy which the space-bound mice received before takeoff.

As fascinating as the interstellar science is, Ramkumar stresses that it’s ultimately an innovative method that’s meant to fill a gap in scientific knowledge and the lives of patients here on the ground (and, yes, some clear implications for the future strategies Oculogenex itself might deploy for its experimental drug pipeline).

“These people often have parents that went blind from the disease, maybe brothers and sisters that are getting injections,” she said. “They’re having trouble seeing in low light conditions, reading the menus in restaurants, trouble reading, barely keeping their driver’s license. Many of these people are living alone and are petrified that they’re about to lose their house and their independence.”

The business of drug development is a fraught endeavor; science can always break your heart, especially for therapies attempting to treat the root causes and not just the symptoms. What Ramkumar and Oculogenex are betting on, and could potentially impact how research scientists and pharma companies at large approach vision loss treatment from the earliest stages, is a clear-eyed view on why it happens in the first place.

https://www.fastcompany.com/91066676/biopharma-space-mice-gene-therapy-vision-loss-oculogenex-spacex-nasa?partner=rss&utm_source=rss&utm_medium=feed&utm_campaign=rss+fastcompany&utm_content=rss

Creată 1y | 21 iun. 2024, 11:20:05


Autentifică-te pentru a adăuga comentarii

Alte posturi din acest grup

Russia restricts WhatsApp and Telegram calls

Russian authorities announced Wednesday they were “partially” restricting calls in messaging apps Telegram and WhatsApp, the latest step in an 

13 aug. 2025, 20:30:08 | Fast company - tech
Amazon expands same-day perishable grocery delivery

Amazon is rolling out a service where its Prime members can now order their blueberries and milk at the same time as basic items like batte

13 aug. 2025, 20:30:07 | Fast company - tech
Most people are using ChatGPT totally wrong—and OpenAI’s CEO just proved it

How did you react to the August 7 release of GPT-5, OpenAI’s latest version of ChatGPT? The company behind the model h

13 aug. 2025, 18:20:04 | Fast company - tech
This mine feeds the tech world and fuels a rebel war

Under the watchful eye of M23 rebels in the hills around the Congolese town of Rubaya, a line of men in rubber boots ferry sacks full of crushed rocks up winding paths cut into the slopes.

13 aug. 2025, 18:20:03 | Fast company - tech
This free web timer puts your computer’s Clock app to shame

For something as simple as setting a timer, the built-in apps on our computers can be awfully fiddly.

Usually you have to open a Clock app first, then navigate to a separate tab for time

13 aug. 2025, 11:20:08 | Fast company - tech
Is agentic AI more than hype? This company thinks it knows how to find out

Over the past five years, advances in AI models’ data processing and r

13 aug. 2025, 11:20:06 | Fast company - tech
How AI can finally fix prior authorization

If you’ve ever been a patient waiting—days, sometimes more than a week—for treatment approval, or a clinician stuck chasing it, you know what prior authorization feels like. Patients sit in limbo,

13 aug. 2025, 11:20:04 | Fast company - tech